Qfitlia does not replace the missing clotting factor. Rather, it reduces the amount of a protein called antithrombin, leading to an increase in thrombin, an enzyme critical for blood clotting. Qfitlia ...

The initial 80-mg monthly dose was abandoned in favor of bimonthly dosing based on antithrombin levels after the fixed dose caused excessive clotting in some patients. Studies using adjustable ...

Subcutaneous Qfitlia does not replace the missing coagulation factor VIII or IX, but reduces the amount of the protein antithrombin, leading to an increase in thrombin, an enzyme critical for ...

WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) has announced the approval of Qfitlia (fitusiran), a treatment designed to prevent or reduce the frequency of bleeding episodes in ...

Qfitlia does not replace the missing clotting factor. Rather, it reduces the amount of a protein called antithrombin, leading to an increase in thrombin, an enzyme critical for blood clotting.